Literature DB >> 21044218

Mechanisms underlying the cerebral microvascular responses to angiotensin II-induced hypertension.

Shantel A Vital1, Satoshi Terao, Mutsumi Nagai, D Neil Granger.   

Abstract

Angiotensin II (AngII) and AngII type-1 receptors (AT1r) have been implicated in the pathogenesis of hypertension and ischemic stroke. The objectives of this study was to determine if/how chronic AngII administration affects blood-brain barrier (BBB) function and blood cell adhesion in the cerebral microvasculature. AngII-loaded osmotic pumps were implanted in wild type (WT) and mutant mice. Leukocyte and platelet adhesion were monitored in cerebral venules by intravital microscopy and BBB permeability detected by Evans blue leakage. AngII (two week) infusion increased blood pressure in WT mice. This was accompanied by an increased BBB permeability and a high density of adherent leukocytes and platelets. AT1r (on the vessel wall, but not on blood cells) was largely responsible for the microvascular responses to AngII. Immunodeficient (Rag-1(-/-) ) mice exhibited blunted blood cell recruitment responses without a change in BBB permeability. A similar protection pattern was noted in RANTES(-/-) and P-selectin(-/-) mice, with bone marrow chimeras (blood cell deficiency only) yielding responses comparable to the respective knockouts. These findings implicate AT1r in the microvascular dysfunction associated with AngII-induced hypertension and suggest that immune cells and blood cell-associated RANTES and P-selectin contribute to the blood cell recruitment, but not the BBB failure, elicited by AngII.
© 2010 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044218      PMCID: PMC3058857          DOI: 10.1111/j.1549-8719.2010.00060.x

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  31 in total

1.  Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor.

Authors:  G Wolf; F N Ziyadeh; F Thaiss; J Tomaszewski; R J Caron; U Wenzel; G Zahner; U Helmchen; R A Stahl
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

2.  AT1 receptor antagonist prevents brain edema without lowering blood pressure.

Authors:  H Ito; K Takemori; J Kawai; T Suzuki
Journal:  Acta Neurochir Suppl       Date:  2000

3.  Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines.

Authors:  Teresa Mateo; Yafa Naim Abu Nabah; May Abu Taha; Manuel Mata; Miguel Cerdá-Nicolás; Amanda E I Proudfoot; Rolf A K Stahl; Andrew C Issekutz; Julio Cortijo; Esteban J Morcillo; Peter J Jose; Maria-Jesus Sanz
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 4.  Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events.

Authors:  Vasilios Papademetriou
Journal:  Am Heart J       Date:  2009-06       Impact factor: 4.749

5.  Adhesion of flowing leucocytes to immobilized platelets.

Authors:  P Lalor; G B Nash
Journal:  Br J Haematol       Date:  1995-04       Impact factor: 6.998

Review 6.  AT(1) receptors and control of blood pressure: the kidney and more...

Authors:  Steven D Crowley; Susan B Gurley; Thomas M Coffman
Journal:  Trends Cardiovasc Med       Date:  2007-01       Impact factor: 6.677

Review 7.  Malignant hypertension and hypertensive emergencies.

Authors:  C Kitiyakara; N J Guzman
Journal:  J Am Soc Nephrol       Date:  1998-01       Impact factor: 10.121

8.  The chemokine CCL5 is essential for leukocyte recruitment in a model of severe Herpes simplex encephalitis.

Authors:  Márcia Carvalho Vilela; Daniel Santos Mansur; Norinne Lacerda-Queiroz; David Henrique Rodrigues; Graciela Kunrath Lima; Rosa Maria Esteves Arantes; Erna Geessien Kroon; Marco Antônio da Silva Campos; Mauro Martins Teixeira; Antônio Lúcio Teixeira
Journal:  Ann N Y Acad Sci       Date:  2009-02       Impact factor: 5.691

Review 9.  Pulmonary immune cells in health and disease: platelets.

Authors:  C M Herd; C P Page
Journal:  Eur Respir J       Date:  1994-06       Impact factor: 16.671

10.  The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

Authors:  Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Björn Dahlöf; Richard B Devereux; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristianson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Steven M Snapinn; Katherine E Harris; Hans Wedel
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-03       Impact factor: 3.738

View more
  33 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Dual opposing roles of adaptive immunity in hypertension.

Authors:  Noureddine Idris-Khodja; Muhammad Oneeb Rehman Mian; Pierre Paradis; Ernesto L Schiffrin
Journal:  Eur Heart J       Date:  2014-03-30       Impact factor: 29.983

Review 3.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  HIF isoforms in the skin differentially regulate systemic arterial pressure.

Authors:  Andrew S Cowburn; Norihiko Takeda; Adam T Boutin; Jung-Whan Kim; Jane C Sterling; Manando Nakasaki; Mark Southwood; Ananda W Goldrath; Colin Jamora; Victor Nizet; Edwin R Chilvers; Randall S Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

5.  Preventing leptin resistance by blocking angiotensin II AT1 receptors in diet-induced obese rats.

Authors:  Helge Müller-Fielitz; Margot Lau; Cathleen Geißler; Lars Werner; Martina Winkler; Walter Raasch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 6.  Blood-brain barrier dysfunction: the undervalued frontier of hypertension.

Authors:  Vasiliki Katsi; Maria Marketou; Spyridon Maragkoudakis; Matthaios Didagelos; Georgios Charalambous; Fragkiskos Parthenakis; Costas Tsioufis; Dimitrios Tousoulis
Journal:  J Hum Hypertens       Date:  2020-05-18       Impact factor: 3.012

7.  Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia.

Authors:  Hizir Kurtel; Stephen F Rodrigues; Cigdem E Yilmaz; Alper Yildirim; D Neil Granger
Journal:  J Am Soc Hypertens       Date:  2013 Jan-Feb

8.  Leukocyte-dependent responses of the microvasculature to chronic angiotensin II exposure.

Authors:  Alper Yildirim; Janice Russell; Li-Sue S Yan; Elena Y Senchenkova; D Neil Granger
Journal:  Hypertension       Date:  2012-10-22       Impact factor: 10.190

9.  Loss of Resistance to Angiotensin II-Induced Hypertension in the Jackson Laboratory Recombination-Activating Gene Null Mouse on the C57BL/6J Background.

Authors:  Hong Ji; Amrita V Pai; Crystal A West; Xie Wu; Robert C Speth; Kathryn Sandberg
Journal:  Hypertension       Date:  2017-04-24       Impact factor: 10.190

Review 10.  The cooperative roles of inflammation and oxidative stress in the pathogenesis of hypertension.

Authors:  Steven D Crowley
Journal:  Antioxid Redox Signal       Date:  2013-04-19       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.